ClinicalTrials.gg
CompletedNCT05823662DJUpdated Apr 24, 2023

Double J Stenting and Sildosin After URSL for Lower Ureteric Stones

An interventional study of DJ stent and Silodosin in Lower Ureteric Stones, Ureteroscopic Lithotripsy and DJ Stenting, sponsored by Benha University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2023-04-24.

Sponsored by Benha University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Mar 2022, registered Mar 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The aim of this prospective comparative clinical study to compare DJ stenting and Sildosin after ureteroscopic lithotripsy for lower ureteric stones.

Read the detailed description

Ureteric calculi are known to affect approximately 10 - 15% of the overall population. The incidence of urolithiasis is rising over time. Most of these stones are known to pass spontaneously with or without expulsive medical therapy. The expulsion of calculus depends on the following factors: the calculus size and the location in the ureter (Alelign and Petros, 2018). The calculi expulsion rates change depending on these factors, with the expulsion rate ranging from 40% to 98% for calculi less than 5 mm. The calculi, which measure 6 mm or more have a spontaneous expulsion rate ranging between 35% to 50%.

Semirigid ureteroscopy (URS) lithotripsy has been shown to have high success rates for treating distal ureteric stones in many studies. However, URS is associated with some drawbacks, which may be risky and sometimes problematic.

The use of Double J (DJ) stent after ureteroscopy helps in the passage of residual fragments and prevents pain caused due to mucosal edema and obstruction. However, many patients complain of stent-related discomfort in the postoperative period. There is an additional need for stent removal, which is another surgical procedure adding to the cost of treatment. Despite its usefulness, the morbidity associated with these stents has been considered a potential health problem. However, many patients complain of stent-related discomfort in the postoperative period. There is an additional need for stent removal, which is another surgical procedure adding to the cost of treatment.

Silodosin is a highly selective alpha-1 adrenergic receptor antagonist which is used in the treatment of lower urinary tract symptoms (LUTS). Alpha-1 adrenergic receptors are densely found in the smooth muscle cells of the lower urinary tract, and silodosin relaxes them and improves the stent-related symptoms (SRS), and various studies have also shown similar effects. It has documented its use in the therapy of ureteric calculus.

02

Conditions studied

  • Lower Ureteric Stones
  • Ureteroscopic Lithotripsy
  • DJ Stenting
03

In context

Lead sponsor

Benha University is the lead sponsor of 364 studies on the registry; 67 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >18 to 60 years,
  • Diagnosed with lower ureteric stone and those patients willing to participate and follow up in the study.

Exclusion criteria

Exclusion Criteria:

  • Patients having a previous or present history of prostatic or bladder surgery, , neurological disorder, pelvic irradiation, and diabetes.
  • Acute or chronic renal insufficiency, solitary kidney or congenital urinary abnormality, cardiac disease, postoperative residual stone fragments, multiple or bilateral ureteral stones, patients with bilateral stents or long-term stenting with frequent change of stents, history of interstitial cystitis, chronic cystitis or prostatitis.
  • Medical treatment (α blockers, beta-blockers, calcium antagonists, 5 alfa reductase inhibitors, phosphodiesterase type 5 inhibitors, anticholinergics and cholinergic, nitrates).
  • Pregnant and lactating women and patients not available for follow-up will be excluded from this study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    DJ stent group

    A 5 Fr double J stent will be inserted and then removed after three weeks.

    Procedure: DJ stent

  • Experimental
    Silodosin group

    Patients will be given one capsule of silodosin 8 mg at the night for three weeks.

    Drug: Silodosin

Interventions

  • ProcedureDJ stent

    A 5 Fr DJ stent will be inserted and then removed after three weeks.

  • Patients will be given one capsule of silodosin 8 mg at the night for three weeks.

06

What researchers measure

Primary outcomes

  1. Stone-free rate

    Stone free rate 24 hours and stone free rate 73 hours Stone free rate 73 hours Stone free rate 24 hours Stone free rate 73 hours Stone free rate will be recorded

    Time frame: 3 weeks

Secondary outcomes

  1. Operative time

    Operative time in minutes will be recorded

    Time frame: Intraoperatively

  2. Comlications

    Complications as fever, flank pain, Lower Urinary lower urinary tract Symptoms or hematuria

    Time frame: 24 hours Postoperative

07

Study locations

1 site
  • Benha University Hospitals
    Benha, Egypt
08

References and documents

Individual participant data

Plan to share: Yes — The study will be available under a reasonable request from the corresponding author.

Supporting information: Study protocol

Time frame: One year after the end of the study

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2022 to primary completion in Mar 2023, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2023
First posted
Apr 21, 2023
StartActual
Mar 2, 2022
Primary completionActual
Mar 2, 2023
CompletionActual
Mar 2, 2023
Last update
Apr 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05823662
Lead sponsor
Benha University
Responsible party
Ahmed Abou Elezz Abdel Fattah (Lecturer of Urology, Faculty of Medicine, Benha University, Benha, Egypt, Benha University) — Principal investigator
First posted
Apr 21, 2023
Start date
Mar 2, 2022
Primary completion
Mar 2, 2023
Completion
Mar 2, 2023
Last update
Apr 24, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Silodosin

Start the discussion